Your Kidney Health Matters.
Now enrolling
PROACT 1 Clinical Trial is a Phase 3 Study enrolling participants with Chronic Kidney Disease (CKD) and Type 2 Diabetes
Your Kidney Health Matters.
Now enrolling
PROACT 1 Clinical Trial is a Phase 3 Study enrolling participants with Chronic Kidney Disease (CKD) and Type 2 Diabetes
Your Kidney Health Matters.
Now enrolling
PROACT 1 Clinical Trial is a Phase 3 Study enrolling participants with Chronic Kidney Disease (CKD) and Type 2 Diabetes
What you should know
Brief Facts about the PROACT 1 Clinical Trial
The PROACT 1 Clinical Trial will last 3-4 years.
To test if an investigational treatment called rilparencel, which is a candidate cell therapy product prepared from your own kidney cells, may help preserve kidney function and potentially delay dialysis in patients with advanced CKD and type 2 diabetes.
- You must have advanced CKD and type 2 diabetes
- Your eGFR should be between 20 and 35 mL/min/1.73.m2
- You must not have a kidney transplant
- There are other study requirements you will have to meet to join
We’re actively enrolling adults ages 30-80 at more than 50 sites across the US.
Compensation for your time and travel will be provided.
- Delay Dialysis: Enrolling in this trial may help preserve kidney function and potentially delay the need to start dialysis.
- Close Monitoring: You have the benefit of getting standard of care from both your doctor and the study.
- Helping Medical Research: You may contribute to doctors’ understanding of CKD, potentially aiding future patients.
- While current treatment options aim to slow kidney disease progression, there is still a significant need for therapies that can preserve kidney function and delay or prevent the need for dialysis in people living with advanced CKD.
If you or a loved one is interested in joining the PROACT 1 clinical trial, take our pre-screening survey today!
